Wednesday, July 16, 2025 7/16/2025

Quantification of ARIA During the Treatment of Alzheimer's Patients

Award Number: R44AG079694
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2024
PERIOD OF PERFORMANCE END DATE: 03/31/2027

Group Awards By:

View Award Description

Quantification of ARIA During the Treatment of Alzheimer's Patients - Project Summary/Abstract Alzheimer’s disease is characterized by β-amyloid deposits and neurofibrillary tangles preceding neuronal loss and cognitive decline. The overall goal of this proposal is to detect and quantify treatment-related changes and abnormalities in Alzheimer patients’ brains using MR images while patients are undergoing amyloid clearing drug treatment. We will develop and validate the lesion detection and quantification software and deploy it as a clinically usable tool. Current detection of ARIA lesions depends on visual detection by trained radiologists. In recent years, multiple amyloid deposit modifying drugs have been developed and used in trials with Alzheimer's disease patients. During these drug trials, it is not uncommon that some patients developed imaging abnormalities in the brain and clinical symptoms. These amyloid-related imaging abnormalities (ARIA) manifest as intracerebral hemorrhage (ARIA-H), and vasogenic edema (ARIA-E). With the recent FDA approval of amyloid-targeting monoclonal antibody aducanumab in Alzheimer’s disease, brain imaging has become an indispensable tool to monitor the patients’ brains during therapy. The current recommendation on use of the amyloid clearing drug aducanumab is to have MRIs prior to initiating therapy, during the titration of the drug, and at any time the patient has symptoms suggestive of ARIA. It is recommended to have dose interruption or treatment discontinuation for symptomatic ARIA and moderate-severe ARIA. In addition, Cerebral Amyloid Angiopathy (CAA) patients also experience ARIA-like lesions in their brains and MRI is the recommended imaging modality to monitor the CAA progression. One would expect that in the near future amyloid deposit modifying drugs will be used in autosomal dominant AD, or other amyloid related diseases such as Levy body dementia concomitant with amyloid beta accumulation, or Down syndrome where amyloid plaques and symptoms of dementia develops later in midlife of the patients. Therefore, a treatment monitoring brain imaging software will have an important role in terms of patient care in a wider set of disease entities where patients are given amyloid clearing drugs.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $932,694 )
2025	2025	CORTECHS LABS, INC.	5060 SHOREHAM PL STE 240	SAN DIEGO	CA	92122	SAN DIEGO	USA	Aging Research	000	2	6/4/2025	EXTENSION WITH OR WITHOUT FUNDS	$932,694
														Subtotal = $932,694

Issue Date FY: 2024 ( Subtotal = $295,759 )
2024	2024	CORTECHS LABS, INC.	5060 SHOREHAM PL STE 240	SAN DIEGO	CA	92122	SAN DIEGO	USA	Aging Research	000	1	7/24/2024	NEW	$295,759
														Subtotal = $295,759

Grand Total All Awards = $1,228,453

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Quantification of ARIA During the Treatment of Alzheimer's Patients

Award Number: R44AG079694

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2024

PERIOD OF PERFORMANCE END DATE: 03/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer